+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Presbyopia - Epidemiology Forecast to 2030

  • ID: 5264919
  • Report
  • March 2021
  • Region: Global
  • 100 pages
  • DelveInsight
This ‘Presbyopia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Presbyopia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Presbyopia Understanding

Presbyopia, a natural age-related condition, is the result of a gradual decrease in accommodative amplitude, from about 15 diopters (D) in early childhood to 1 D before the age of 60 years. An irreversible, normal physiologic condition that affects all primates, it impairs the ability to see clearly at near. It is a natural part of aging. Presbyopia usually becomes noticeable in the early to mid-40s and continues to worsen until around age 65. Presbyopia can be classified by type which includes incipient presbyopia, functional presbyopia, absolute presbyopia, premature presbyopia, and nocturnal presbyopia. Presbyopia is partly due to age-related changes in the proteins within the lens of the eye that cause it to become thicker, harder, and less flexible. This loss of flexibility affects the lens's ability to refract light rays which, in turn, affects the eye's capacity to focus.

Initial symptoms may be difficulties with prolonged close-up work, with tiring (eye strain) of the eyes. This may be worse in dim light. Other common symptoms are delays in focusing at near or distance, ocular discomfort, headache, asthenopia, squinting, fatigue or drowsiness from near work, increased working distance, need for brighter light for reading, and diplopia. Age is the major risk factor for the development of presbyopia, although the condition may occur prematurely as the result of factors such as trauma, systemic disease, cardiovascular disease, or a drug side effect.

Presbyopia cannot be prevented. It is an inevitable part of aging. However, people who do a lot of close visual work, such as working with a computer or intensive reading, may develop presbyopia earlier than others.

Presbyopia Diagnosis

Presbyopia can be diagnosed by an optometrist, ophthalmologist, or physician, who takes a complete medical history to determine the extent of the vision problem. The doctor also tests the vision by having the patient read the text at a typically comfortable distance. If the diagnosis of presbyopia is confirmed, the doctor may perform a test to determine the extent of the focusing problem and the appropriate lens prescription. In this test, the doctor asks the patient to look through corrective lenses and continues to increase the magnification power until the words on the page are clear and comfortable enough to be read by the patient. A thorough assessment of the health of the eyes and associated structures is an integral component of the comprehensive adult eye and vision examination. This examination can lead to the diagnosis of systemic diseases and disorders that have ocular manifestations.

Epidemiology Perspective

The Presbyopia epidemiology division provides insights about historical and current Presbyopia patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2020, the total prevalent case of Presbyopia was 286,994,105 cases in the 7MM which are expected to grow during the forecast period, i.e., 2021-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Presbyopia epidemiology [segmented as Total Prevalent Cases of Presbyopia, Total Diagnosed Cases of Presbyopia, Total Age-specific Cases of Presbyopia, Gender-specific Cases of Presbyopia, Severity-specific Cases of Presbyopia, and Total Treated cases of Presbyopia] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Presbyopia Epidemiology

Estimates show that the highest cases of Presbyopia in the 7MM were in the United States, followed by Germany, Japan, Italy, France, the United Kingdom, and Spain in 2020.
  • In the United States, the total number of prevalent cases of Presbyopia was 117,369,699 cases in the year 2020 which are expected to grow during the forecast period, i.e., 2021-2030.
  • In the year 2020, the total prevalent cases of Presbyopia were 134,726,460 cases in EU-5 which are expected to grow during the forecast period, i.e., 2021-2030.
  • In Japan, the total number of prevalent cases of Presbyopia was 34,897,947 cases in the year 2020 which are expected to grow during the forecast period, i.e., 2021-2030.
Scope of the Report
  • The Presbyopia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The Presbyopia Report and Model provide an overview of the risk factors and global trends of Presbyopia in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Presbyopia in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Presbyopia.
  • The report provides the segmentation of the Presbyopia epidemiology by total prevalent cases in the 7MM.
  • The report provides the segmentation of the Presbyopia epidemiology by total diagnosed cases in the 7MM.
  • The report provides the segmentation of the Presbyopia epidemiology by total age-specific cases in the 7MM.
  • The report provides the segmentation of the Presbyopia epidemiology by gender-specific cases in the 7MM.
  • The report provides the segmentation of the Presbyopia epidemiology by severity-specific cases in the 7MM.
  • The report provides the segmentation of the Presbyopia epidemiology by treated cases in the 7MM.
Report Highlights
  • 10-Year Forecast of Presbyopia epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Presbyopia
  • Total Diagnosed Cases of Presbyopia
  • Total Age-Specific Cases of Presbyopia
  • Gender-Specific Cases of Presbyopia
  • Severity-Specific Cases of Presbyopia
  • Treated Cases of Presbyopia
KOL Views

The publisher interviews KOL's and SME's opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM concerning the patient population of Presbyopia?
  • What are the key findings of the Presbyopia epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018-2030)?
  • What would be the total number of patients of Presbyopia across the 7MM during the study period (2018-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2018-2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2018-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Presbyopia?
Reasons to Buy

The Presbyopia Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Presbyopia market
  • Quantify patient populations in the global Presbyopia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Presbyopia therapeutics in each of the markets covered
  • Understand the magnitude of Presbyopia population by its severity
  • The Presbyopia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Presbyopia Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030
  • In the 7MM, the total diagnosed cases of Presbyopia was 246,336,607 cases in the year 2020, which will probably rise during the forecast period, i.e., 2021-2030.
  • In the 7MM, the total gender-specific cases of Presbyopia were 98,534,643 for males and 147,801,964 for females in the year 2020.
  • In the 7MM, the total age-specific cases of Presbyopia were 70,036,878, 80,546,882, 58,274,618, and 37,478,227 cases for the age group less than 60 years, 60-69, 70-79, and ≥80 years, respectively in 2020.
  • In the 7MM, the total severity-specific cases of Presbyopia were 49,267,321 and 197,069,285 for mild cases and moderate to severe cases, respectively in the year 2020.
  • In the 7MM, the total treated cases of Presbyopia was 197,069,285 cases in the year 2020, which will probably rise during the forecast period, i.e., 2021-2030.
Note: Product cover images may vary from those shown
1. Key Insights

2. Report Introduction

3. Executive Summary of Presbyopia

4. Epidemiology Methodology

5. Disease Background and Overview
5.1. Introduction
5.1.1. Signs and Symptoms of Presbyopia
5.1.2. Difference between Presbyopia and Hyperopia
5.1.3. Risk Factors and Causes of Presbyopia
5.1.4. Pathophysiology of Presbyopia
5.1.5. Complications of Presbyopia
5.2. Diagnosis of Presbyopia
5.3. Patient History
5.4. Ocular Examination
5.4.1. Visual Acuity
5.4.2. Keratometry/Topography
5.4.3. Refraction
5.4.4. Binocular Vision and Accommodation
5.5. Supplemental Testing
5.6. Eye health evaluation
5.7. Recommended eye examination frequency for pediatric patients and adults
5.8. Differential Diagnosis

6. Early Detection and Prevention of Presbyopia

7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Epidemiology of Presbyopia
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Prevalent Cases of Presbyopia
7.3.2. Total Diagnosed Cases of Presbyopia
7.3.3. Total Age-specific Cases of Presbyopia
7.3.4. Gender-specific Cases of Presbyopia
7.3.5. Severity-specific Cases of Presbyopia
7.3.6. Total Treated Cases of Presbyopia

8. The United States
8.1. Total Prevalent Cases of Presbyopia
8.2. Total Diagnosed Cases of Presbyopia
8.3. Total Age-specific Cases of Presbyopia
8.4. Gender-specific Cases of Presbyopia
8.5. Severity-specific Cases of Presbyopia
8.6. Total Treated Cases of Presbyopia

9. EU-5
9.1. Germany
9.1.1. Total Prevalent Cases of Presbyopia
9.1.2. Total Diagnosed Cases of Presbyopia
9.1.3. Total Age-specific Cases of Presbyopia
9.1.4. Gender-specific Cases of Presbyopia
9.1.5. Severity-specific Cases of Presbyopia
9.1.6. Total Treated Cases of Presbyopia
9.2. France
9.2.1. Total Prevalent Cases of Presbyopia
9.2.2. Total Diagnosed Cases of Presbyopia
9.2.3. Total Age-specific Cases of Presbyopia
9.2.4. Gender-specific Cases of Presbyopia
9.2.5. Severity-specific Cases of Presbyopia
9.2.6. Total Treated Cases of Presbyopia
9.3. Italy
9.3.1. Total Prevalent Cases of Presbyopia
9.3.2. Total Diagnosed Cases of Presbyopia
9.3.3. Total Age-specific Cases of Presbyopia
9.3.4. Gender-specific Cases of Presbyopia
9.3.5. Severity-specific Cases of Presbyopia
9.3.6. Total Treated Cases of Presbyopia
9.4. Spain
9.4.1. Total Prevalent Cases of Presbyopia
9.4.2. Total Diagnosed Cases of Presbyopia
9.4.3. Total Age-specific Cases of Presbyopia
9.4.4. Gender-specific Cases of Presbyopia
9.4.5. Severity-specific Cases of Presbyopia
9.4.6. Total Treated Cases of Presbyopia
9.5. The United Kingdom
9.5.1. Total Prevalent Cases of Presbyopia
9.5.2. Total Diagnosed Cases of Presbyopia
9.5.3. Total Age-specific Cases of Presbyopia
9.5.4. Gender-specific Cases of Presbyopia
9.5.5. Severity-specific Cases of Presbyopia
9.5.6. Total Treated Cases of Presbyopia

10. Japan
10.1. Total Prevalent Cases of Presbyopia
10.2. Total Diagnosed Cases of Presbyopia
10.3. Total Age-specific Cases of Presbyopia
10.4. Gender-specific Cases of Presbyopia
10.5. Severity-specific Cases of Presbyopia
10.6. Total Treated Cases of Presbyopia

11. Appendix
11.1. Bibliography
11.2. Report Methodology

12. Publisher Capabilities

13. Disclaimer

14. About the Publisher

List of Tables
Table 1: Summary of Presbyopia Epidemiology
Table 2: Common risk factors of presbyopia
Table 3: Recommended examination frequency for the pediatric patient
Table 4: Recommended examination frequency for the adult patient
Table 5: Total Prevalent Cases of Presbyopia in the 7MM, in Thousands (2018-2030)
Table 6: Total Diagnosed Cases of Presbyopia in the 7MM, in Thousands (2018-2030)
Table 7: Total Age-specific Cases of Presbyopia in the 7MM, in Thousands (2018-2030)
Table 8: Gender-specific Cases of Presbyopia in the 7MM, in Thousands (2018-2030)
Table 9: Severity-specific Cases of Presbyopia in the 7MM, in Thousands (2018-2030)
Table 10: Total Treated Cases of Presbyopia in the 7MM, in Thousands (2018-2030)
Table 11: Total Prevalent Cases of Presbyopia in the United States, in Thousands (2018-2030)
Table 12: Total Diagnosed Cases of Presbyopia in the United States, in Thousands (2018-2030)
Table 13: Total Age-specific Cases of Presbyopia in the United States, in Thousands (2018-2030)
Table 14: Gender-specific Cases of Presbyopia in the United States, in Thousands (2018-2030)
Table 15: Severity-specific Cases of Presbyopia in the United States, in Thousands (2018-2030)
Table 16: Total Treated Cases of Presbyopia in the United States, in Thousands (2018-2030)
Table 17: Total Prevalent Cases of Presbyopia in Germany, in Thousands (2018-2030)
Table 18: Total Diagnosed Cases of Presbyopia in Germany, in Thousands (2018-2030)
Table 19: Total Age-specific Cases of Presbyopia in Germany, in Thousands (2018-2030)
Table 20: Gender-specific Cases of Presbyopia in Germany, in Thousands (2018-2030)
Table 21: Severity-specific Cases of Presbyopia in Germany, in Thousands (2018-2030)
Table 22: Total Treated Cases of Presbyopia in Germany, in Thousands (2018-2030)
Table 23: Total Prevalent Cases of Presbyopia in France, in Thousands (2018-2030)
Table 24: Total Diagnosed Cases of Presbyopia in France, in Thousands (2018-2030)
Table 25: Total Age-specific Cases of Presbyopia in France, in Thousands (2018-2030)
Table 26: Gender-specific Cases of Presbyopia in France, in Thousands (2018-2030)
Table 27: Severity-specific Cases of Presbyopia in France, in Thousands (2018-2030)
Table 28: Total Treated Cases of Presbyopia in France, in Thousands (2018-2030)
Table 29: Total Prevalent Cases of Presbyopia in Italy, in Thousands (2018-2030)
Table 30: Total Diagnosed Cases of Presbyopia in Italy, in Thousands (2018-2030)
Table 31: Total Age-specific Cases of Presbyopia in Italy, in Thousands (2018-2030)
Table 32: Gender-specific Cases of Presbyopia in Italy, in Thousands (2018-2030)
Table 33: Severity-specific Cases of Presbyopia in Italy, in Thousands (2018-2030)
Table 34: Total Treated Cases of Presbyopia in Italy, in Thousands (2018-2030)
Table 35: Total Prevalent Cases of Presbyopia in Spain, in Thousands (2018-2030)
Table 36: Total Diagnosed Cases of Presbyopia in Spain, in Thousands (2018-2030)
Table 37: Total Age-specific Cases of Presbyopia in Spain, in Thousands (2018-2030)
Table 38: Gender-specific Cases of Presbyopia in Spain, in Thousands (2018-2030)
Table 39: Severity-specific Cases of Presbyopia in Spain, in Thousands (2018-2030)
Table 40: Total Treated Cases of Presbyopia in Spain, in Thousands (2018-2030)
Table 41: Total Prevalent Cases of Presbyopia in the United Kingdom, in Thousands (2018-2030)
Table 42: Total Diagnosed Cases of Presbyopia in the United Kingdom, in Thousands (2018-2030)
Table 43: Total Age-specific Cases of Presbyopia in the United Kingdom, in Thousands (2018-2030)
Table 44: Gender-specific Cases of Presbyopia in the United Kingdom, in Thousands (2018-2030)
Table 45: Severity-specific Cases of Presbyopia in the United Kingdom, in Thousands (2018-2030)
Table 46: Total Treated Cases of Presbyopia in the United Kingdom, in Thousands (2018-2030)
Table 47: Total Prevalent Cases of Presbyopia in Japan, in Thousands (2018-2030)
Table 48: Total Diagnosed Cases of Presbyopia in Japan, in Thousands (2018-2030)
Table 49: Total Age-specific Cases of Presbyopia in Japan, in Thousands (2018-2030)
Table 50: Gender-specific Cases of Presbyopia in Japan, in Thousands (2018-2030)
Table 51: Severity-specific Cases of Presbyopia in Japan, in Thousands (2018-2030)
Table 52: Total Treated Cases of Presbyopia in Japan, in Thousands (2018-2030)

List of Figures
Figure 1: Epidemiology Methodology
Figure 2: Presbyopia compared to a Normal eye
Figure 3: Symptoms of Presbyopia
Figure 4: Causes of Presbyopia
Figure 5: Anatomy of the eye
Figure 6: Pathogenesis of Presbyopia
Figure 7: Differential diagnosis of presbyopia
Figure 8: Total Prevalent Cases of Presbyopia in the 7MM (2018-2030)
Figure 9: Total Diagnosed Cases of Presbyopia in the 7MM (2018-2030)
Figure 10: Total Age-specific Cases of Presbyopia in the 7MM (2018-2030)
Figure 11: Gender-specific Cases of Presbyopia in the 7MM (2018-2030)
Figure 12: Severity-specific Cases of Presbyopia in the 7MM (2018-2030)
Figure 13: Total Treated Cases of Presbyopia in the 7MM (2018-2030)
Figure 14: Total Prevalent Cases of Presbyopia in the United States (2018-2030)
Figure 15: Total Diagnosed Cases of Presbyopia in the United States (2018-2030)
Figure 16: Total Age-specific Cases of Presbyopia in the United States (2018-2030)
Figure 17: Gender-specific Cases of Presbyopia in the United States (2018-2030)
Figure 18: Severity-specific Cases of Presbyopia in the United States (2018-2030)
Figure 19: Total Treated Cases of Presbyopia in the United States (2018-2030)
Figure 20: Total Prevalent Cases of Presbyopia in Germany (2018-2030)
Figure 21: Total Diagnosed Cases of Presbyopia in Germany (2018-2030)
Figure 22: Total Age-specific Cases of Presbyopia in Germany (2018-2030)
Figure 23: Gender-specific Cases of Presbyopia in Germany (2018-2030)
Figure 24: Severity-specific Cases of Presbyopia in Germany (2018-2030)
Figure 25: Total Treated Cases of Presbyopia in Germany (2018-2030)
Figure 26: Total Prevalent Cases of Presbyopia in France (2018-2030)
Figure 27: Total Diagnosed Cases of Presbyopia in France (2018-2030)
Figure 28: Total Age-specific Cases of Presbyopia in France (2018-2030)
Figure 29: Gender-specific Cases of Presbyopia in France (2018-2030)
Figure 30: Severity-specific Cases of Presbyopia in France (2018-2030)
Figure 31: Total Treated Cases of Presbyopia in France (2018-2030)
Figure 32: Total Prevalent Cases of Presbyopia in Italy (2018-2030)
Figure 33: Total Diagnosed Cases of Presbyopia in Italy (2018-2030)
Figure 34: Total Age-specific Cases of Presbyopia in Italy (2018-2030)
Figure 35: Gender-specific Cases of Presbyopia in Italy (2018-2030)
Figure 36: Severity-specific Cases of Presbyopia in Italy (2018-2030)
Figure 37: Total Treated Cases of Presbyopia in Italy (2018-2030)
Figure 38: Total Prevalent Cases of Presbyopia in Spain (2018-2030)
Figure 39: Total Diagnosed Cases of Presbyopia in Spain (2018-2030)
Figure 40: Total Age-specific Cases of Presbyopia in Spain (2018-2030)
Figure 41: Gender-specific Cases of Presbyopia in Spain (2018-2030)
Figure 42: Severity-specific Cases of Presbyopia in Spain (2018-2030)
Figure 43: Total Treated Cases of Presbyopia in Spain (2018-2030)
Figure 44: Total Prevalent Cases of Presbyopia in the United Kingdom (2018-2030)
Figure 45: Total Diagnosed Cases of Presbyopia in the United Kingdom (2018-2030)
Figure 46: Total Age-specific Cases of Presbyopia in the United Kingdom (2018-2030)
Figure 47: Gender-specific Cases of Presbyopia in the United Kingdom (2018-2030)
Figure 48: Severity-specific Cases of Presbyopia in the United Kingdom (2018-2030)
Figure 49: Total Treated Cases of Presbyopia in the United Kingdom (2018-2030)
Figure 50: Total Prevalent Cases of Presbyopia in Japan (2018-2030)
Figure 51: Total Diagnosed Cases of Presbyopia in Japan (2018-2030)
Figure 52: Total Age-specific Cases of Presbyopia in Japan (2018-2030)
Figure 53: Gender-specific Cases of Presbyopia in Japan (2018-2030)
Figure 54: Severity-specific Cases of Presbyopia in Japan (2018-2030)
Figure 55: Total Treated Cases of Presbyopia in Japan (2018-2030)
Note: Product cover images may vary from those shown
Adroll
adroll